Chase Pelletier is an up-and-coming kart racer from Canada who is 14 years old. When he got type 1 diabetes just before his eleventh birthday, he recalls, "It was pretty overwhelming at first. But me and my family decided early on that we're not going to get down on diabetes in general, and we're going to try to think of positive ways to deal with it."
What if there were a technology that could make people with type 1 diabetes feel absolutely wonderful, completely healthy, better than they ever realized was possible? And what if it were about to disappear? Well, there is such a technology, and it is in serious jeopardy. It's called the implantable insulin pump, currently made by Medtronic. This is the story of four people who have been using this device for 20 years, and their desperate crusade to keep it from disappearing forever.
A couple of diabetes recalls are in the works, one for a group of insulin cartridges manufactured by Animas and another for the entire line of ACCU-CHEK® FlexLink Plus infusion sets, manufactured by Roche.
Calibra Medical has announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its FinesseTM insulin patch-pen for up to three-day use with Novo Nordisk's Novolog® rapid-acting insulin. This much-anticipated step closer to market release follows the announcement in January that Calibra received FDA clearance for the device for use with Eli Lilly's Humalog® rapid-acting insulin.
Researchers at Sansum Diabetes Research Institute and University of California, Santa Barbara have concluded that changing the height of a conventional insulin pump in relation to its tubing and infusion set can significantly impact expected insulin delivery rates. Such changes can occur during routine daily activities like dressing, sleeping or showering. The study, "Siphon Effects of Continuous Subcutaneous Insulin Infusion Pump Delivery Performance," evaluated the siphon or hydrostatic pressure action effects on continuous subcutaneous insulin infusion and was published in the January issue of Journal of Diabetes Science and Technology.
When Smiths Medical announced in late March that it was discontinuing the manufacture and sales of its Deltec Cozmo insulin pumps, the company's annual sales of that product were about $36 million. In contrast, Medtronic, manufacturer of the Minimed line of insulin pumps reported sales of $727 million in the nine months from April 2008 to January 2009.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.